Serine protease inhibitor Kazal type 1 (SPINK1) promotes proliferation, migration, invasion and radiation resistance in rectal cancer patients receiving concurrent chemoradiotherapy: a potential target for precision medicine

Serine peptidase inhibitor Kazal type-1 (SPINK1), a trypsin kinase inhibitor, is known to be associated with inflammation and pathogenesis. The aim in this study was to demonstrate the clinicopathological role and progression of SPINK1 in rectal cancer (RC) patients undergoing concurrent chemoradiot...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yi-Ting, Tseng, Tzu-Ting, Tsai, Hung-Pei, Kuo, Shih-Hsun, Huang, Ming-Yii, Wang, Jaw-Yuan, Chai, Chee-Yin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515043/
https://www.ncbi.nlm.nih.gov/pubmed/36053457
http://dx.doi.org/10.1007/s13577-022-00776-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515043/
https://www.ncbi.nlm.nih.gov/pubmed/36053457
http://dx.doi.org/10.1007/s13577-022-00776-4

Ejemplares similares